

Oxford Protein Production Facility

The Thermofluor Method

Joanne Nettleship Oxford Protein Production Facility PEPC5 4th September 2006







Background and Methodology

Design and use of a general screen


Focussed ligand-binding assays

Limitations

Background


- A biophysical technique used to study (relative) protein stabilities
- The solution is heated stepwise from room temperature to ~95°C and fluorescence is monitored at each step
- Rising temperature causes protein unfolding and the fluorophore (SYPRO Orange) partitions itself into the melted protein and hence the overall effect is an increase in fluorescence with increasing temperature
- If a drug/ligand is included which binds to the protein, the mid-point of the melt curve can shift, indicating stabilising or destabilising effects (e.g. Ligand binding)

Increasing temperature




Methodology


- Assay volume is 15-50 µl with typically 0.1 mg/ml protein (1.5 µg protein per well)
- Use of SYPRO Orange dye allows detection using filters present in a standard RT-PCR machine (Excitation at 473nm and emission at 570nm)
- Each reaction contains only protein and dye – drugs or ligands of interest are added as required
- Heat sample plate from 20 to 90°C in 0.2 °C steps, holding for 12 seconds to read fluorescence



Melt Curves



Protein Stabilisation




Temperature Cycling Profiles


Melt

 fluorescence read at various temperatures


Heat and Cool

- fluorescence always read at same temperature
- takes longer than a melt





Comparison of 'Heat and Cool' with 'Melt'



The change in Tm is the same for "heat and cool" and "melt"

Equipment in the OPPF



BioRad Opticon 2 Real-Time PCR Dectector

Plates: Standard white thin-walled PCR plates

 Seals: BioRad Microseal
– optically clear, adhesive seals

Design and Use of a General Screen

Design of a General Screen

96-well PCR plate format

Contains common changes in buffer condition – pH, type of buffer, salts, etc.

 Used to find stable buffer conditions for unstable proteins

Contains common ligands – NAD, ATP, etc.


- Used to find stabilising ligands and to give information on the function of "unknown" proteins.
- Provides information for co-crystallisation experiments.

Design of a General Screen

	1	2	3	4	5	6	7	8	9	10	11	12	
A	NaAc pH4.0	NaAc pH4.4	Citrate pH5.0	Citrate pH5.4	Cacodyl pH6.0	Cacodyl pH6.4	HEPES pH7.0	HEPES pH7.4	TRIS pH8.0	TRIS pH8.4	CAPSO pH 9.0	CAPO pH 9.4	No Salt
В	NaAc pH4.0	NaAc pH4.4	Citrate pH5.0	Citrate pH5.4	Cacodyl pH6.0	Cacodyl pH6.4	HEPES pH7.0	HEPES pH7.4	TRIS pH8.0	TRIS pH8.4	CAPSO pH 9.0	CAPO pH 9.4	100mM NaCl
С	NaAc pH4.0	NaAc pH4.4	Citrate pH5.0	Citrate pH5.4	Cacodyl pH6.0	Cacodyl pH6.4	HEPES pH7.0	HEPES pH7.4	TRIS pH8.0	TRIS pH8.4	CAPSO pH 9.0	CAPO pH 9.4	200mM NaCl
D	NaAc pH4.0	NaAc pH4.4	Citrate pH5.0	Citrate pH5.4	Cacodyl pH6.0	Cacodyl pH6.4	HEPES pH7.0	HEPES pH7.4	TRIS pH8.0	TRIS pH8.4	CAPSO pH 9.0	CAPO pH 9.4	500mM NaCl
E	ATP	ADP	AMP	AMPC CP	AMPc PP	AMP PcP	UTP	GTP	GDP	GTP- γS	TMP	FAD	
F	β-NAD	β–γ Methyl GTP	dCMP	dGMP	ssDNA 7mer	ssDNA 9mer	1% glycerol	5% glycerol	10% glycerol	20% glycerol	1mM DTT	5mM DTT	Ac
G	CaCl	MgCl	MnCl	ZiCl	FeCl	KCI	LiCl	Thyio cyanate	L- Proline	Phenol	DMSO	NiCl	Additives
н	Glycine	Sperm- idine	10mM Urea	PEG 400	D(+)- Glucose	D- Galact ose	Alanine	Methio nine	Serine	Arg inine	n-Octyl- β–D- gluco- pyrano side	n- Dodecyl β-D- malto side	

Use of the General Screen


OPPF2956



- Protein is more stable in higher salt and pH.
- Protein is stabilised by nucleotides, Ca, Mg, proline and arginine.
- OPPF2956 is a DNA binding protein.

Destabilised No Change Stabilised


OPPF1446



- Protein is more stable in higher salt and pH.
- Protein is destabilised by DTT, detergent, Zn, Fe, FAD, TMP.
- OPPF1446 is a dimer which is known to be inactive when dissociated with reducing agents.

Destabilised No Change Stabilised





- Protein is more destabilised outside pH7-9.
- **Salt** concentration has no effect on protein stability.
- OPPF2398 is an intracellular domain of a single membrane spanning receptor.

Destabilised No Change Stabilised

Use in Structural Genomics

 Allows measurement of buffer conditions which favour protein stability:
– Change of purification buffers and protocol
– Prevention of protein aggregation

Screens to find a potential ligands and co-factors:

- Used in purification to stabilise protein
- Co-crystallisation trials


Focussed Ligand-binding Assays

Focussed Sugar-Binding Assay


C-type lectin

Protein binds β-glucans
Structure revealed unpredicted metal binding site
Test the activity of refolded protein
Test any metal binding activity

Melt Curve and Derivative Curve



Assay Results and Conclusions



Sugar binding confirmed by ~10°C shift – confirmed protein correctly refolded


Metal binding confirmed by ~5°C shift

Focussed Amino Acid-Binding Assays


OPPF1345 and OPPF2146

Proteins bind amino acids
Apo crystal structures have been solved
Test the binding of different amino acids
Use the data for soaking experiments in order to gain crystal structures with co-factors bound

Assay results




OPPF1345 Alanine Binding



Co-crystallisation with alanine have been used to obtain a crystals of *holo*-OPPF1345

OPPF2146 Amino-Acid Binding



Soaks with methionine and leucine have been used to obtain a crystal structures of the protein with amino acids bound

Use in Structural Genomics

Allows quantification of known ligand binding

Allows exact ligand to be ascertained eg. NAD⁺/NADH/NADP⁺/NADPH

Gives information for crystal soaks or co-crystallisation experiments

Limitations

Some proteins do not give a satisfactory melt curve

Some co-factors/ligands interact with the dye to give a false positive result

For a full 96-well screen the technique uses 0.5-1.2mg of protein

References

Methodology:

- Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, Carver T, Asel E, Springer BA, Lane P (2001) *Journal of Biomolecular Screening* 6: 429-440
- Lo MC, Aulabaugh A, Jin GX, Cowling R, Bard J, Malamas M, Ellestad G (2004). Analytical Biochemistry 332: 153-159

Examples:

- Matulis D, Kranz JK, Salemme FR, Todd MJ (2005) *Biochemistry* 44: 5258-5266
- Carver TE, Bordeau B, Cummings MD, et al (2005) Journal of Biological Chemistry 280: 11704-11712
- Constantine KL, Krystek SR, Healy MD, Doyle ML, Siemers NO, Thanassi J, Yan N, Xie DL, Goldfarb V, Yanchunas J, Tao L, Dougherty BA, Farmer BT (2005) *Protein Science* 14: 1472-1484
- El Omari K, Bird LE, Nicholes CE, Ren JS, Stammers DK (2005) Journal of Biological Chemistry 280: 18229-18236

Oxford Protein Production Facility

Acknowledgements

Methodology:

Focussed screens:

James Brown

General Screen:

James BrownSarah Sainsbury

Tom Walter
Erika Mancini
Christian Siebold

OPPF members and management





